Osteoporosis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Osteoporosis - Pipeline Review, H2 2018’, provides an overview of the Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteoporosis

- The report reviews pipeline therapeutics for Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Osteoporosis therapeutics and enlists all their major and minor projects

- The report assesses Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Osteoporosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Osteoporosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abreos Biosciences Inc

Alvogen Korea Co Ltd

Amgen Inc

Asahi Kasei Corp

BiosanaPharma BV

Biosion Inc

Bone Biologics Corp

Bristol-Myers Squibb Co

Cadila Healthcare Ltd ...

Abreos Biosciences Inc

Alvogen Korea Co Ltd

Amgen Inc

Asahi Kasei Corp

BiosanaPharma BV

Biosion Inc

Bone Biologics Corp

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

ChoDang Pharm Co Ltd

Chugai Pharmaceutical Co Ltd

Corium International Inc

Daewon Pharm Co Ltd

Daiichi Sankyo Co Ltd

Dong Wha Pharma Co Ltd

Eli Lilly and Co

EndoCeutics Inc

Entera Bio Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Enzo Biochem Inc

Evgen Pharma Plc

Gador SA

Genor BioPharma Co Ltd

GL Pharm Tech Corp

GlycoNex Inc

Hanmi Pharmaceuticals Co Ltd

Haoma Medica Ltd

Huons Global Co Ltd

Immunwork Inc

Innovent Biologics Inc

InSight Biopharmaceuticals Ltd

Intas Pharmaceuticals Ltd

Ipsen SA

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Lead Discovery Center GmbH

Lotus Pharmaceutical Co Ltd

Lupin Ltd

Luye Pharma Group Ltd

mAbxience SA

Merck & Co Inc

Millendo Therapeutics Inc

Nano Intelligent Biomedical Engineering Corp

Omeros Corp

Oncobiologics Inc

Paras Biopharmaceuticals Finland Oy

Pfenex Inc

PhytoHealth Corp

R Pharm

Reliance Life Sciences Pvt Ltd

Ribomic Inc

Richter Gedeon Nyrt

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Shin Poong PharmCo Ltd

Sinil Pharmaceutical Co Ltd

Stelis Biopharma Pvt Ltd

Terpenoid Therapeutics Inc

TSH Biopharm Corporation Ltd

Uni-Bio Science Group Ltd

Viking Therapeutics Inc

ViroMed Co Ltd

Wroclawskie Centrum Badan EIT+ Sp z oo

Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Osteoporosis – Overview 7

Osteoporosis – Therapeutics Development 8

Osteoporosis – Therapeutics Assessment 25

Osteoporosis – ...

Table of Contents

Table of Contents 2

Introduction 6

Osteoporosis – Overview 7

Osteoporosis – Therapeutics Development 8

Osteoporosis – Therapeutics Assessment 25

Osteoporosis – Companies Involved in Therapeutics Development 35

Osteoporosis – Drug Profiles 66

Osteoporosis – Dormant Projects 239

Osteoporosis – Discontinued Products 247

Osteoporosis – Product Development Milestones 249

Appendix 258

List of Tables

List of Tables

Number of Products under Development for Osteoporosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Osteoporosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Osteoporosis – Pipeline by Abreos Biosciences Inc, H2 2018

Osteoporosis – Pipeline by Alvogen Korea Co Ltd, H2 2018

Osteoporosis – Pipeline by Amgen Inc, H2 2018

Osteoporosis – Pipeline by Asahi Kasei Corp, H2 2018

Osteoporosis – Pipeline by BiosanaPharma BV, H2 2018

Osteoporosis – Pipeline by Biosion Inc, H2 2018

Osteoporosis – Pipeline by Bone Biologics Corp, H2 2018

Osteoporosis – Pipeline by Bristol-Myers Squibb Co, H2 2018

Osteoporosis – Pipeline by Cadila Healthcare Ltd, H2 2018

Osteoporosis – Pipeline by ChoDang Pharm Co Ltd, H2 2018

Osteoporosis – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Osteoporosis – Pipeline by Corium International Inc, H2 2018

Osteoporosis – Pipeline by Daewon Pharm Co Ltd, H2 2018

Osteoporosis – Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Osteoporosis – Pipeline by Dong Wha Pharma Co Ltd, H2 2018

Osteoporosis – Pipeline by Eli Lilly and Co, H2 2018

Osteoporosis – Pipeline by EndoCeutics Inc, H2 2018

Osteoporosis – Pipeline by Entera Bio Ltd, H2 2018

Osteoporosis – Pipeline by Enteris BioPharma Inc, H2 2018

Osteoporosis – Pipeline by Enzene Biosciences Ltd, H2 2018

Osteoporosis – Pipeline by Enzo Biochem Inc, H2 2018

Osteoporosis – Pipeline by Evgen Pharma Plc, H2 2018

Osteoporosis – Pipeline by Gador SA, H2 2018

Osteoporosis – Pipeline by Genor BioPharma Co Ltd, H2 2018

Osteoporosis – Pipeline by GL Pharm Tech Corp, H2 2018

Osteoporosis – Pipeline by GlycoNex Inc, H2 2018

Osteoporosis – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Osteoporosis – Pipeline by Haoma Medica Ltd, H2 2018

Osteoporosis – Pipeline by Huons Global Co Ltd, H2 2018

Osteoporosis – Pipeline by Immunwork Inc, H2 2018

Osteoporosis – Pipeline by Innovent Biologics Inc, H2 2018

Osteoporosis – Pipeline by InSight Biopharmaceuticals Ltd, H2 2018

Osteoporosis – Pipeline by Intas Pharmaceuticals Ltd, H2 2018

Osteoporosis – Pipeline by Ipsen SA, H2 2018

Osteoporosis – Pipeline by JHL Biotech Inc, H2 2018

Osteoporosis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Osteoporosis – Pipeline by Lead Discovery Center GmbH, H2 2018

Osteoporosis – Pipeline by Lotus Pharmaceutical Co Ltd, H2 2018

List of Figures

List of Figures

Number of Products under Development for Osteoporosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Osteoporosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports